MAIA Biotechnology raises $736,600 in private placement

CHICAGO - MAIA Biotechnology, Inc. (NYSE American:MAIA), a $50 million market cap biotech firm whose shares have declined 12% over the past week according to InvestingPro, announced Monday it has entered into definitive agreements to sell 603,769 shares of common stock at $1.22 per share in a private placement to accredited investors.

The transaction, expected to close around Wednesday, includes warrants allowing investors to purchase an additional share of common stock for each share purchased, at an exercise price of $1.52 per share. These warrants will become exercisable six months after issuance and will remain valid for three years.

According to the press release statement, MAIA plans to use the proceeds, expected to be approximately $736,600 before expenses, to fund Step 1 of Part C of its Phase II THIO-101 trial and for working capital.

The securities are being offered through a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws.

MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Its lead program, ateganosine (THIO), is in clinical development for the treatment of non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.

The transaction remains subject to customary closing conditions.

In other recent news, Maia Biotechnology has announced several key developments. The company revealed it will issue 440,503 shares after entering into inducement offer agreements with accredited investors, allowing them to exercise outstanding warrants at a reduced price of $1.30 per share. Additionally, Maia Biotechnology presented efficacy data from its Phase 2 THIO-101 clinical trial at the 2025 IASLC World Conference on Lung Cancer, showcasing its study on THIO combined with the immune checkpoint inhibitor cemiplimab in advanced non-small cell lung cancer patients. The U.S. Food and Drug Administration granted Fast Track designation to Maia’s experimental lung cancer drug ateganosine, potentially accelerating its regulatory process. This designation pertains to its development for treating non-small cell lung cancer, currently under evaluation in a pivotal Phase 2 clinical trial. Furthermore, the company published promising preclinical data on its second-generation ateganosine prodrugs platform in the journal Nucleic Acids Research. The study highlights potential new molecules for enhancing cancer treatment and overcoming drug resistance. These developments mark significant progress for Maia Biotechnology in its ongoing research and clinical efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.